objective The diagnostic use of procalcitonin for bacterial infections remains a matter of debate. So far most studies used ambiguous outcome measures such as sepsis instead of infection. We performed a systematic review and meta-analysis to investigate the diagnostic accuracy of procalcitonin for bacteraemia, a proven bloodstream infection.
aBstrac t objective
The diagnostic use of procalcitonin for bacterial infections remains a matter of debate. So far most studies used ambiguous outcome measures such as sepsis instead of infection. We performed a systematic review and meta-analysis to investigate the diagnostic accuracy of procalcitonin for bacteraemia, a proven bloodstream infection.
methods We searched all major databases from inception to June 2014 for original, English written, research articles that studied the diagnostic accuracy between procalcitonin and positive blood cultures in adult patients. We calculated the area under the summary receiver-operating characteristic curves (SROC) and pooled sensitivities and specificities. To minimise potential heterogeneity we performed subgroup analyses.
results In total 58 of 1,567 eligible studies were included in the meta-analysis and provided a total of 16,514 patients of whom 3,420 suffered from bacteraemia. In the overall analysis the SROC was 0.79. The optimal and most widely used procalcitonin cutoff value was 0.5 ng/mL with a corresponding sensitivity of 76% and specificity of 69%. In subgroup analyses the lowest SROC was found in immunocompromised/ neutropenic patients (0.71), the highest SROC was found in intensive care patients (0.88), sensitivities ranging 66-89% and specificities 55-78%.
conclusions In spite of study heterogeneity, procalcitonin had a fair diagnostic accuracy for bacteraemia in adult patients suspected of infection or sepsis. In particular low procalcitonin levels can be used to rule out the presence of bacteraemia. Further research on the safety and efficacy of procalcitonin as a single diagnostic tool to withhold taking blood cultures is needed.
introd uction
Infection and the subsequent sepsis syndrome are associated with morbidity and mortality. 1, 2 The fear of undertreatment leads to the routine collection of specimen for microbiological culture and initiation of empiric antibiotic therapy. 3 On the other hand, antibiotic overuse increases microbial selection and resistance and can cause adverse drug reactions. 4 To assist the diagnosis of infection in clinical practice its symptoms have been grouped into the systemic inflammatory response syndrome (SIRS). 5 A clinically suspected or proven infection in the presence of SIRS is termed sepsis. 5 In recent years authors have studied the use of biomarkers, like procalcitonin, to improve the diagnosis of the sepsis syndrome rather than of proven infection. [6] [7] [8] [9] The use of the sepsis syndrome as a surrogate for proven infection as an outcome parameter may be too sensitive and nonspecific. This could partially explain the contradicting results in previous studies [6] [7] [8] [9] 10 and meta-analyses on the diagnostic use of procalcitonin for sepsis.
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The definition of proven local infection remains matter of debate and we therefore study the more robustly defined proven bloodstream infections, i.e. bacteraemia.
Bacteraemia can be identified in about 30% of septic patients and necessitates further diagnostic evaluation. 19 However, culture results take several days and can be falsely negative in patients on antibiotic treatment. [20] [21] [22] Recent studies demonstrated that procalcitonin can accurately predict bacteraemia in patients with community-acquired pneumonia, 23 acute fever, 24 and in elderly patients suspected of infection. 25 Procalcitonin can also accurately discriminate between true bacteraemia and coagulase negative staphylococci-contaminated blood cultures. 26 Another study demonstrated that bacteraemia is unlikely when procalcitonin levels are low. 27 Some meta-analyses focused on the diagnostic value of procalcitonin for microbiologically confirmed local infection [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] or bacteraemia. 40 However, the number of included studies was small, specific patient subgroups were analysed or studies concerning sepsis were included as well. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] We therefore performed a systematic review and meta-analysis to investigate the diagnostic accuracy of procalcitonin for bacteraemia. Our hypothesis is that in adult patients suspected for infection or sepsis procalcitonin is a useful biomarker of bacteraemia.
method s search s t r a t e g y a n d s t u d y s e l ec t i on
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting this systematic review and meta-analysis. 41 A flow-chart of the literature search can be found in Figure 1 . All prospective and retrospective, original, observational (case-control, cross sectional, cohort and longitudinal) studies published in English from inception until June 2014 were considered eligible for inclusion. Studies were screened by title and abstract and definite inclusion was decided upon after full text review.
We included studies on adult hospitalised patients suspected of infection or sepsis, in which bacteraemia with a known pathogen was confirmed by blood culture and measurement of procalcitonin levels was performed within 24 hours of inclusion. Studies had to give a detailed description of patient groups and demographic variables.
The comparison of procalcitonin levels had to be between hospitalised patients with Search databases: PubMed, Medline, Embase, ISI Web of Knowledge, the Cochrane Library, Scopus, BioMed Central, and Science Direct.
Search strategy: (procalcitonin OR PCT) AND (bacterial infection OR bacteraemia OR bloodstream infection).
Records identified after primary search (N=1567)
Records excluded (n=1443) 
Quality a s s e s s m e n t
We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool, 42 scores range from 0 to 14, to assess the methodological quality of included studies.
s tatistic a l m e t h od s
To avoid double inclusion of the same patient group we only included one sensitivity and specificity from each article, unless results clearly came from different patient groups. We used the bivariate random-effects regression model for pooling the sensitivity and specificity estimates, as recommended by the Cochrane Diagnostic Test Accuracy Working Group. 43 The bivariate model takes into account the potential trade-off between sensitivity and specificity by explicitly incorporating this negative correlation in the analysis. 44, 45 Cutoff values differed among the included studies, the cutoff value closest to 0.5 ng/mL was used for the analysis if multiple cutoff values were given.
The 0.5 ng/ml cutoff was chosen based on recommendations of the manufacturer, current literature [46] [47] [48] [49] and was the cutoff used most often in the included studies (Table   1 ). Summary receiver-operating characteristics curves (SROC) were drawn using the 50 We expected substantial heterogeneity in the of the overall analysis and in order to obtain more homogenous results subgroup analysis were performed. First, we calculated the diagnostic accuracy in specific patient subgroups based on their underlying disease. We calculated the diagnostic accuracy in studies comparing bacteraemia vs. non-bacteraemia in patients with SIRS and comparing bacteraemia vs. non-bacteraemia in patients with SIRS developing localised infections. When a specific subgroup for the controls could not be identified we categorised the study in the category non-bacteraemia. We studied the diagnostic accuracy of procalcitonin for bacteraemia in immunocompromised/neutro- 
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The mean or median age is provided, if mean/median was not provided, the mean age was manually calculated of the subgroups. Studies in which patients were excluded because of antibiotic use prior to PCT measurement are marked with an *. All studies have a prospective study design, retrospective studies are marked with penic and immunocompetent patients separately. We categorised all studies according to department of inclusion. Finally, we also studied retrospective studies separately from prospective studies. We tested for a threshold effect by adding a covariate for threshold to the bivariate model.
We used IBM statistics 21.0 (IBM SPSS, Chicago, IL, USA) and R 3.1.1 (Vienna, Austria XX) to analyse the data. The R package mada was used to perform the pooling of sensitivity and specificity and generating of SROC-curves. Pooled sensitivity and specificity estimates were generated, with their 95% confidence interval (CI). To assess heterogeneity among studies I 2 and X 2 /cochrane Q statistics were performed.
We used the Deeks funnel plot asymmetry test to evaluate potential publication bias.
51
P<0.10 for the slope coefficient is considered as significant asymmetry, which indicates potential publication bias. All other tests were two-sided and a P<0.05 was considered statistically significant; exact P-values >0.001 are given.
results literatu r e s e a r c h
The literature search resulted in a total of 1,567 articles of which 1,443 studies were excluded because of: written language other than English (N=118), age <18 years (N=759), in vitro/animal studies (N=57) or lack of original data (reviews, metaanalysis, case reports, editorials, commentaries and letters, meeting abstract, poster presentations, N=509). We performed a full text review of the 124 articles considered eligible for inclusion, which resulted in the exclusion of another 66 studies whom did not provide AUC values/ sensitivity/ specificity (N=29), did not study bacteraemia (N=26), did not compare to non-bacteraemia (N=4), studied candidaemia (N=3), used healthy controls (N=2), did not provide the procalcitonin level for bacteraemia (N=1), or used a longitudinal study design and analysis (N=1). The remaining 58
articles were used in the meta-analysis. The complete reference list containing all in-and excluded studies is presented in the supplemental material. Table 2 depicts the 66 studies excluded after full text review. 
s tudy c h a r a c t e r i s t i c s a n d q u a l i ty a ss es sm en t

the dia g n os t i c a c c u r a c y of p r oca l c i t oni n for ba c t er a em i a
In the overall analysis the area under the SROC was 0.79 ( Figure 2 and Table 4 ).
The optimal and most widely used procalcitonin cutoff value was 0.5 ng/mL (Table 5) and corresponded with a 76% sensitivity and 69% specificity (Table 4 ). In Figure 3 , the sensitivity and specificity per study are given. The lowest SROC was found in immunocomprised/neutropenic patients (0.71), the highest SROC (0.88) in ICU patients.
The lowest sensitivity was found in immunocomrpomised/neutropenic patients (66), the highest in ICU patients (89) . The lowest specificity was found in patients with localised infections (55) and the highest in immunocompromised/neutropenic patients (78) . Table 6 shows the 2x2 tables with low positive predictive values (17-28%) and high negative predictive values (95-98%) for different hospital settings at the 0.5 ng/ mL procalcitonin cutoff. There was significant heterogeneity in the overall analysis and in most subgroups (Table 4) . However, there was no indication of a threshold-effect.
evaluat ion of p u b l i c a ti on b i a s
Figure 4 displays the Deeks funnel plot asymmetry test of this meta-analysis. The
Deeks test was not statistically significant (P=0.13) indicating that there is no direct evidence for publication bias. The quality assessment of studies of diagnostic accuracy checklist. Item 1: Was the spectrum of patients representative of the patients who will receive the test in practice?; 2: Were selection criteria clearly described?; 3: Is the reference standard likely to correctly classify the target condition?; 4: Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?; 5:Did the whole study population or a random selection of the sample, receive verification using a reference standard for diagnosis?; 6: Did patients receive the same reference standard regardless of the index test result?; 7: Was the reference standard independent of the index test?; 8: Was the execution of the index test described in sufficient detail to permit replication of the test?; 9: Was the execution of the reference standard described in sufficient detail to permit its replication? figure 2. Summary receiver-operating characteristic (SROC) curve plot of procalcitonin for the diagnosis of bacteraemia, including all studies (N=58).
Individual studies are shown as open circles. Summary point is shown as a closed square, representing sensitivity estimates pooled by using bivariate random-effects regression model. The area under the SROC curve (dashed line) is 0.79, pooled sensitivity 76% and specificity 69%. The 95% confidence region displays the 95% confidence interval of the pooled sensitivity and specificity. The 95% prediction region is the region for a forecast of the true sensitivity and specificity in a future study. that PCT should not be used as single diagnostic tool for infection. 34 However their conclusion was based on only four studies on the diagnostic accuracy of procalcitonin for bacterial infection in elderly patients. 34 As far as we know there is only one previous meta-analysis on the diagnostic accuracy of procalcitonin for bacteraemia with an area under the SROC of 0.84, sensitivity 76%, specificity 70%. 40 This study concluded that widespread use of procalcitonin is not recommended because of the moderate diagnostic accuracy of PCT to predict bacteraemia. 40 This conclusion was based on 17 included studies of which not all contained bacteraemia as primary endpoint. Even though previous meta-analyses showed similar results their conclusion differ, possibly due to differences in interpretation of clinically useful AUC values. In contrast to our study, the above-mentioned meta-analyses only used a small selection of the available literature or used sepsis syndrome and not microbiologically documented infection as their endpoint. Our study shows that procalcitonin can be used in the diagnostic process of bacteraemia regardless of its clinical symptoms. As shown in Table 6 low procalcitonin levels can be used to rule out the presence of bacteraemia in different clinical settings.
This meta-analysis has several limitations. There is some evidence for a concentration-response relation between procalcitonin levels and probability of infection and disease severity. 52 The definition of our primary outcome measure, bacteraemia,
does not acknowledge such a concentration-response relation. Only a minority of the studies in this meta-analysis formally excluded patients treated with antibiotics prior to inclusion. 23, 24, [53] [54] [55] [56] [57] We cannot be certain that false negative results, due to possible antibiotic treatment prior to inclusion, led to underestimation of the effect. Even though the effect size is only fair (area under the SROC 0.79) its direction is positive in almost all studies, in spite of heterogeneity. High I-squares are to be expected because of the variation in cutoffs used in the different included studies and sensitivity and specificity both depend on cutoffs.
To homogenise the results we attempted to use the sensitivities and specificities corresponding with the cutoff value closest to 0.5 ng/mL if multiple cutoff values were given. Other potential factors that could have contributed to heterogeneity are variety in inclusion criteria, underlying diseases, co-morbidities, clinical course and treatment prior to inclusion, variety in the control groups used for comparison against bacteraemia, department of sample collection, and differences in test performance of the various procalcitonin assays. In order to reduce the influence of these factors on heterogeneity we performed analyses in the supposedly more homogeneous patient subgroups. As to be expected, substantial heterogeneity remained in most subgroups. A Funnel plot analysis based on the standard error of the lnDOR can be misleading, therefore we evaluated potential publication bias using the recommended effective sample size-based funnel plots and associated regression tests of asymmetry according to Deeks. 51 conclus ion s
In conclusion, this systematic review and meta-analysis shows that procalcitonin has a fair diagnostic accuracy for bacteraemia in adult, hospitalised patients suspected of infection or sepsis. In particular low procalcitonin levels can be used to rule out the presence of bacteraemia. Further research on the safety and efficacy of using procalcitonin as a single diagnostic tool to withhold taking blood cultures remains to be proven.
